Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT04295538 |
| Consolidated Lead Sponsor | AbbVie |
| Therapeutic Condition Cohort | Rare Genetic, Women's Health, and Other |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 60 participants (ACTUAL) |
| Registered Start Date | 2020-09-06 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| UC Davis Comprehensive Cancer Center | Sacramento, CA | Open Hospital Dossier -> |
| Northwestern Memorial and Lurie Cancer Center | Chicago, IL | Open Hospital Dossier -> |
| Brigham and Women's Hospital | Boston, MA | Open Hospital Dossier -> |
| Beth Israel Deaconess Medical Center | Boston, MA | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.